For example, programmed cell death ligand 1 (PD-L1) and low levels of TILs were both associated with poor clinical prognosis in BRCA patients, which provides a scientific basis for the use of immune checkpoint blockade (ICB) therapy in BRCA patients (Zhu et al., 2019). Here, CD274 is linked to invasive breast carcinoma.